Second Covid-19 vaccine about to get clearance for approval in US

Moderna’s vaccine is safe and 94 percent effective, regulators say, clearing the way for US emergency authorisation. 

Examination by the Food and Drug Administration (FDA) means that it will become the second coronavirus vaccine to be allowed in the US. Americans around the world started to receive Pfizer-BioNTech vaccine jabs a day ago.The death count of the coronavirus in the United States has reached 300,000, according to Johns Hopkins University.The approval of the Moderna vaccine by FDA scientists was confirmed two days before the vaccine panel convened to review the emergency approval.

What were their findings?

The 54-page paper claimed that there were no specific safety concerns and that significant adverse reactions were unlikely. If accepted later this week by the team of experts and the FDA Chief of Vaccine, shipments could start within 24 hours.The FDA found a 94.1 per cent effectiveness rate in the 30,000-person experiment, according to the paper released.The most common side effects included fever, fatigue, and muscle and joint pain.The FDA released related data from Pfizer last week before voting for approval.Moderna was established in 2010 and has never had an FDA approved product so far.The company’s stocks have risen by almost 700 per cent so far this year.

How does it differ from the Pfizer jab?

Moderna vaccine needs temperatures of around-20C for shipping-similar to standard freezers. The Pfizer Jab needs temperatures close to-75C, rendering transport logistics even more complicated.Including the Pfizer Jab, the Moderna vaccine still requires a second booster dose. The second Jab of Moderna comes 28 days after the first Jab.The company is headquartered in Cambridge, Massachusetts, and has claimed that if it were approved, the “vast majority” of its vaccine would be developed there.Pfizer’s medicine is being developed in a variety of countries, including Germany and Belgium.

– BBC

Leave a Reply

Your email address will not be published. Required fields are marked *